Navigation Links
Amylin to Present Data Showing Investigational Metreleptin Treatment Led to Long-Term Improvements in Diabetes and Lipid Control in Patients with Lipodystrophy
Date:4/15/2011

ction of the BLA by the end of this year, which will complete the application. If approved, metreleptin would be the first therapy indicated specifically for the treatment of diabetes and high triglycerides in patients with lipodystrophy, and the first approved therapeutic use of metreleptin.

About Amylin Pharmaceuticals, Inc.

Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information on Amylin Pharmaceuticals is available at www.amylin.com.

This press release contains forward-looking statements about Amylin which involve risks and uncertainties.  The actual results for Amylin could differ materially from those discussed due to a number of risks and uncertainties, including that the CMC section of the metreleptin BLA mentioned in this press release may not be submitted in a timely fashion, the estimate of the number of lipodystrophy patients mentioned in this press release may not be accurate, clinical trials or studies may not start when planned, confirm previous results, be predictive of real world use or achieve intended clinical endpoints; preclinical studies may not be predictive; our product candidates, including the product candidate mentioned in this press release, may not receive regulatory approval; and inherent scientific, regulatory and other risks in the drug development and commercialization process. These and additional risks and uncertainties are described more fully in Amyli
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
2. Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
3. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
4. Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009
5. Amylin Pharmaceuticals Reports Third Quarter Financial Results
6. Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDAs BYETTA(R) (Exenatide) Injection Update
7. Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference
8. Amylin Pharmaceuticals to Webcast Year-End Financial Results
9. Amylin Highlights 2010 Corporate Priorities at J.P. Morgan Healthcare Conference
10. Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity
11. Amylin Pharmaceuticals to Present at The Barclays Capital 2010 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... 2015  Holographic Optical Technologies of Augusta, ... medical imaging, is entering the world of consumer electronics ... April 20 th , 2015, the campaign will introduce ... and 22-inch displays will allow consumers to view fully ... In addition to the two displays, the company will ...
(Date:3/27/2015)... , March 27, 2015 A new report from ... America – Chile , ... are top targets for IVD firms.  The healthcare research firm ... into IVD strategies for the Latin American continent with a ... globally distributed supply operations. However, the country,s regional economic clout ...
(Date:3/27/2015)... Report Details  New study shows ... What does the future hold for top companies ... new report shows you potential revenues to 2025, assessing ... 242-page report provides 185 tables, charts, and graphs. Discover ... future market prospects. Our new study lets you assess ...
Breaking Medicine Technology:Holographic Optical Technologies brings cutting-edge holograms to consumer market through upcoming Kickstarter campaign 2Holographic Optical Technologies brings cutting-edge holograms to consumer market through upcoming Kickstarter campaign 3Kalorama: Beyond Brazil, Latin American IVD Market Grows 2Kalorama: Beyond Brazil, Latin American IVD Market Grows 3Kalorama: Beyond Brazil, Latin American IVD Market Grows 4Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 2Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 3Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 4Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 5Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 6Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 7
(Date:3/27/2015)... Top medical tourism firm, VisitandCare.com ... the Dominican Republic to benefit from the experience of ... the medical tourism industry upside-down and becoming a choice ... services becoming the central influence. , “Trust is ... are not only attracted to low-cost surgical enhancement, but ...
(Date:3/27/2015)... 27, 2015 The report “CountryFocus ... an essential source of information on and analysis ... Germany. Germany’s increasingly elderly population and its associated ... market. In 2013, the elderly accounted for 27.1% ... Compound Annual Growth Rate (CAGR) of 1.2% to ...
(Date:3/27/2015)... March 27, 2015 DrugDev announced company ... Easy was named to the 2015 Philadelphia Business Journal ... list spotlights 40 dynamic, up-and-coming leaders less than 40 ... involvement. Winners are honored at an awards program in ... Philadelphia Business Journal. , Lyn Kremer, Publisher of the ...
(Date:3/27/2015)... According to Health Day , ... Neonatal Abstinence Syndrome (NAS) are causing alarm for Florida ... withdrawal process for a month of their lives- and ... and vomiting. The condition is precipitated by drug use ... treatment (and employing medically assisted drug treatment) will also ...
(Date:3/27/2015)... 2015 California’s ongoing worst ever drought, ... and the United States Northeast, are both manifestations of ... atmosphere is creating changes in the atmosphere’s “energy balance,” ... former NASA researcher, speaking on the Sharon Kleyne Hour™ ... only a warmer and dryer global climate but also ...
Breaking Medicine News(10 mins):Health News:Dominican Republic Plastic Surgery Provider Turning Medical Tourism Upside-Down 2Health News:Dominican Republic Plastic Surgery Provider Turning Medical Tourism Upside-Down 3Health News:Germany Healthcare, Regulatory and Reimbursement Landscape Market Research Report Available at RnRMarketResearch.com 2Health News:Germany Healthcare, Regulatory and Reimbursement Landscape Market Research Report Available at RnRMarketResearch.com 3Health News:Germany Healthcare, Regulatory and Reimbursement Landscape Market Research Report Available at RnRMarketResearch.com 4Health News:DrugDev Founder Melissa Easy is 2015 Philadelphia Business Journal 40 Under 40 Honoree 2Health News:In Florida Only 10% of Pregnant Mothers Are Referred to Drug Rehab Despite Testing Positive for Narcotics 2Health News:California Drought, Boston Blizzards Both Attributed to Global Climate Change Reports Climatologist to Fresh Water Advocate 2Health News:California Drought, Boston Blizzards Both Attributed to Global Climate Change Reports Climatologist to Fresh Water Advocate 3
... , , SALT LAKE ... it has added 10 new sales representatives to its nationwide direct sales ... , , "We,re thrilled to be adding so ... vice president of sales and marketing at Dynatronics. "This is just ...
... , , EMERYVILLE, Calif., ... ) today announced that it will webcast an investor briefing ... Time. Speakers will review clinical data for Nexavar in breast ... 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress in ...
... , , C.S. Mott Children,s Hospital ... to have their children vaccinated against H1N1 flu, despite higher disease risk; ... ANN ARBOR, Mich., Sept. 24 With schools back in session, H1N1 ... children. A new vaccine against H1N1 flu -- strongly recommended for kids ...
... , , SAN ... company discovering and developing a new class of naturally occurring ... in Tokyo on Tuesday October 6. Jeff Watkins, CEO of ... product engine, and lead program based on naturally occurring resected ...
... N.J., Sept. 24 Marketing Technology Solutions , ... QualityHealth.com , has today filed a lawsuit alleging that ... misappropriated trade secrets and other confidential information by utilizing MTS-copyrighted online ... a health website owned and operated by MediZine. , , ...
... Singapore and Washington DC (September 24, 2009) There is clear ... cancer, according to a study published in the current issue ... The article "Lifestyle Interventions in the Prevention and Treatment ... common forms of cancer (lung, colorectal, breast, prostate and skin) ...
Cached Medicine News:Health News:Dynatronics Expands Nationwide Direct Sales Force by 25 Percent 2Health News:H1N1 Flu: Are Parents Underestimating Risk to Kids? 2Health News:H1N1 Flu: Are Parents Underestimating Risk to Kids? 3Health News:H1N1 Flu: Are Parents Underestimating Risk to Kids? 4Health News:aTyr Pharma to Present at Japan Biopharma Partnering Conference 2Health News:MediZine Named in Intellectual Property Lawsuit Filed by Marketing Technology Solutions 2
For the quantitative determination of alkaline phosphatase in human serum....
Auto LDL-Cholesterol, automated analyzer test kits....
Storage temperature: 15 - 30C, linearity: 0 - 20 mg/dL, expected value: male: 3.0 - 7.0 mg/dL and female: 2.2 - 6.2 mg/dL. Available with calibrator and number of tests 125....
For the quantitative determination of Uric Acid in serum. Linearity: 25 mg/dl....
Medicine Products: